NVNO ENVVENO MEDICAL CORPORATION revenue, earnings and financials
For the quarter ended June 30, 2026, ENVVENO MEDICAL CORPORATION reported revenue of n/a, net income of −$3.60M and diluted EPS of −$5.37; for the fiscal year ended December 2025 revenue was n/a.
NVNO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$20.9M, net income −$19.5M (margin n/a), EPS −$33.06
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$23.8M, net income −$21.8M (margin n/a), EPS −$44.53
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$25.2M, net income −$23.5M (margin n/a), EPS −$1.91
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$24.9M, net income −$24.7M (margin n/a), EPS −$2.20
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$16.9M, net income −$16.5M (margin n/a), EPS −$1.90
NVNO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.60M, EPS −$5.37
- Quarter ended Mar 31, 2026: revenue n/a, net income −$3.85M, EPS −$5.89
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$3.74M, EPS −$13.56
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.54M, EPS −$0.23
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.69M, EPS −$11.52
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.50M, EPS −$7.75
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.23M, EPS −$43.56
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.64M, EPS −$0.35
- Quarter ended Jun 30, 2024: revenue n/a, net income −$4.96M, EPS −$0.31
- Quarter ended Mar 31, 2024: revenue n/a, net income −$4.99M, EPS −$0.31
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.65M, EPS −$0.31
- Quarter ended Sep 30, 2023: revenue n/a, net income −$5.00M, EPS −$0.45
- Quarter ended Jun 30, 2023: revenue n/a, net income −$6.47M, EPS −$0.58
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.39M, EPS −$0.57
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$6.18M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.10M, EPS −$0.54
- Quarter ended Jun 30, 2022: revenue n/a, net income −$7.06M, EPS −$0.63
- Quarter ended Mar 31, 2022: revenue n/a, net income −$5.33M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$8.99M, EPS −$0.88
- Quarter ended Sep 30, 2021: revenue n/a, net income −$2.39M, EPS −$0.26
NVNO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$15.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$16.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$18.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$15.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$11.8M, share buybacks n/a
NVNO balance sheet
- Jun 30, 2026: cash $2.84M, total assets $22.7M, total liabilities $1.99M, shareholders' equity $20.7M
- Mar 31, 2026: cash $2.60M, total assets $26.1M, total liabilities $2.35M, shareholders' equity $23.7M
- Dec 31, 2025: cash $3.07M, total assets $29.6M, total liabilities $2.43M, shareholders' equity $27.1M
- Sep 30, 2025: cash $1.54M, total assets $32.4M, total liabilities $2.91M, shareholders' equity $29.4M
- Jun 30, 2025: cash $2.04M, total assets $36.6M, total liabilities $3.52M, shareholders' equity $33.1M
- Mar 31, 2025: cash $2.94M, total assets $40.6M, total liabilities $2.27M, shareholders' equity $38.3M
- Dec 31, 2024: cash $1.75M, total assets $45.0M, total liabilities $2.80M, shareholders' equity $42.2M
- Sep 30, 2024: cash $17.9M, total assets $50.4M, total liabilities $3.02M, shareholders' equity $47.4M
Is NVNO profitable?
No. ENVVENO MEDICAL CORPORATION lost $15.7M over the last four quarters.
What is NVNO's EPS?
Diluted earnings per share over the last four quarters were −$25.05; −$5.37 in the latest quarter.